REFERENCES
- Verrando R, Robaeys G, Mathei C, Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg 2005; 68:81–85.
- White JM, Lopatko OV. Opioid maintenance: A comparative review of pharmacological strategies. Expert Opin Pharmacother 2007; 8:1–11.
- Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation Trial. Am J Addict 2004; 13(Suppl 1):S29–41.
- Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addict 2001; 96:683–690.
- Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: A comparison among the available pharmacological options. Expert Opin Pharmacother 2004; 5:713–725.
- Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis 1998; 186:35–43.
- Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacol 1995; 119:268–276.
- Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004; CD002207.
- Smith KW, Larson MJ. Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts. Am J Drug Alcohol Abuse 2003; 29:323–335.
- Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: A three-year follow-up of quality of life assessment. Scientific World Journal 2005; 5:452–468.
- Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28:321–329.
- Giacomuzzi S, Kemmler G, Ertl M, Riemer Y. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants. Subst Use Misuse 2006; 41:223–244.
- Ponizovsky AM, Grinshpoon A, Margolis A, Cohen R, Rosca P. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine. Addict Behav 200; 31:2002–2013.
- Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull 1993; 29:321–326.
- Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 2005; 162:1171–1178.
- Ritsner M, Modai I, Endicott J, Rivkin O, Nechamkin Y, Barak P, Goldin V, Ponizovsky A. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61:880–889.
- Sunderwirth SG, Milkman H. Behavioral and neurochemical commonalities in addiction. Cont Fam Ther 1991; 13:421–433.
- Stimmel B, Kreek MJ. Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med 2000; 67:375–380.
- Bruera E, Sweeney C. Methadone use in cancer patients with pain: A review. J Palliat Med 2002; 5:127–138.
- Ausubel DP. Methadone maintenance treatment: The other side of the coin. Int J Addict 1983; 18:851–862.
- Jasinski DR, Preston KL. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 1986; 17:301–310.
- Zissi A, Barry MM, Cochrane R. A mediational model of quality of life for individuals with severe mental health problems. Psychol Med 1998; 28:1221–1230.
- Comer SD, Sullivan MA, Walker EA. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. J Pharmacol Exp Ther 2005; 315:1320–1330.